Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842321 | 1.00 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL2844473 | 1.00 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326815 | 0.94 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326817 | 0.94 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL729266 | 0.94 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL31327361 | 0.92 | SLC6A3 (0.58) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL12996843 | 0.91 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL9915339 | 0.91 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326261 | 0.89 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL10326440 | 0.89 | SLC6A3 (0.47) | SLC6A3SLC6A2SLC6A4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107667097-B | Separation of enantiomers of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 诺瓦色生物公司 | 2021-02-12 | — | — | CN | claimed |
| EP-3303308-B1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY SA (CH) | 2019-10-09 | — | — | EP | claimed |
| US-10150723-B2 | Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one | NOVASSAY S.A. (CH) | 2018-12-11 | — | — | US | claimed |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY S.A. (CH) | 2018-05-17 | — | — | US | claimed |
| CN-115745764-B | Preparation method of milbelin intermediate | 重庆华森制药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-115745764-A | Preparation method of milobalin intermediate | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-107667097-B | Separation of enantiomers of 3-ethylbicyclo [3.2.0] hept-3-en-6-one | 诺瓦色生物公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3303308-B1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY SA (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10150723-B2 | Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one | NOVASSAY S.A. (CH) | 2018-12-11 | — | — | US | disclosed |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | NOVASSAY S.A. (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-7884223-B2 | N-isopropylphenethylamine; N-(2,6-dimethoxybenzyl)1-phenethylamine; (R,R) N-(1-naphth-1-ylethyl)-1-phenethylamine; high activity; easily accessible | DSM IP ASSETS B.V. (NL) | 2011-02-08 | — | — | US | disclosed |
| US-7884223-B2 | N-isopropylphenethylamine; N-(2,6-dimethoxybenzyl)1-phenethylamine; (R,R) N-(1-naphth-1-ylethyl)-1-phenethylamine; high activity; easily accessible | DSM IP ASSETS B.V. (NL) | 2011-02-08 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-1824868-B1 | CHIRAL COMPOUND SUITABLE AS A CATALYST FOR ASYMMETRIC TRANSFER HYDROGENATION | DSM IP ASSETS BV (NL) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009147843-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | PATHEON HOLDINGS I B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | SLC6A3 4843/4885SLC6A2 4820/4885SLC6A4 4697/4885 |
| US-20180134643-A1 | SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO[3.2.0]HEPT-3-EN-6-ONE | ALDH7A1, OPRK1, SCN3A | SLC6A3 1750/4885SLC6A2 1257/4885SLC6A4 2620/4885 |
| US-10150723-B2 | Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one | ALDH7A1, OPRK1, SCN3A | SLC6A3 1750/4885SLC6A2 1257/4885SLC6A4 2620/4885 |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | SLC30A6, SLC39A14, SLC30A5 | SLC6A3 370/4885SLC6A2 626/4885SLC6A4 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.